Join the Liraglutide group to help and get support from people like you.
Liraglutide News (Page 2)
The New Definition of Obesity
The way obesity is diagnosed needs to become more sophisticated, an international commission has concluded. Using body-mass index (BMI) to tell who is overweight or obese is not reliable, and can...
Perioperative GLP-1 RA Use Reduces Risk for Complications in Patients With Diabetes
MONDAY, Jan. 13, 2025 – For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with...
Some GLP-1s Achieve More Weight Loss Than Others: Study
WEDNESDAY, Jan. 8, 2025 – Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been approved for that purpose. A new evidence review published ...
GLP-1 RAs Efficacious for Weight Loss in Overweight, Obesity Without Diabetes
TUESDAY, Jan. 7, 2025 – For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious for weight loss, according to a review published...
FDA Approves First Generic Liraglutide Once-Daily Injection
THURSDAY, Dec. 26, 2024 – The U.S. Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 (GLP-1) receptor...
FDA Approves Generic GLP-1 Medicine, Liraglutide, (a Victoza Generic), For Diabetes Treatment
THURSDAY, Dec. 26, (2024 HealthDay News) – The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a daily injectable GLP-1 medicine for people ...
FDA Approves First Generic of GLP-1 Receptor Agonist Victoza (liraglutide injection) to Lower Blood Sugar in Patients with Type 2 Diabetes
December 23, 2024 – Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1)...
Stroke Guidelines Updated, With Focus on Women and GLP-1s
MONDAY, Nov. 25, 2024 – Women, especially those who had high blood pressure during pregnancy or entered menopause before age 45, are among those with a greater risk for stroke. They and other...
Semaglutide, Liraglutide May Reduce Hospitalization Risk for Alcohol Use Disorder
FRIDAY, Nov. 22, 2024 – Semaglutide and liraglutide are associated with a reduced risk for hospitalization due to alcohol use disorder (AUD), according to a study published online Nov. 13 in JAMA...
Glucagon-Like Peptide-1 Receptor Agonists May Reduce Alcohol Consumption
THURSDAY, Nov. 21, 2024 – Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals, according to a study published online Nov....
More Evidence That GLP-1 Meds Curb Alcohol Abuse
FRIDAY, Nov. 15, 2024 – There have been a slew of studies recently supporting the notion that the same mechanisms that help folks lose weight with Ozempic and its kin also work to curb problem...
ASH: GLP-1 RA Use Tied to Lower Rate of Venous Thromboembolism in Diabetes
THURSDAY, Nov. 14, 2024 – For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a lower risk for venous thromboembolism (VTE),...
Ozempic Could Help Curb Alcoholism
WEDNESDAY, Nov. 13, 2024 – The blockbuster GLP-1 drug semaglutide (Ozempic, Wegovy) could curb drinking for people battling alcohol use disorder, helping them to avoid crises that require...
AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke Survivors
TUESDAY, Nov. 12, 2024 – For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced...
Expanding Access to Obesity Medications Could Avert 42,000 Deaths/Year
THURSDAY, Nov. 7, 2024 – Expanding access to obesity medications such as glucagon-like peptide 1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide and GLP-1 receptor agonists could...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Diabetes, Type 2, Cardiovascular Risk Reduction